Comparative Pharmacology
Head-to-head clinical analysis: DIMETANE TEN versus SUDAFED 12 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIMETANE TEN versus SUDAFED 12 HOUR.
DIMETANE-TEN vs SUDAFED 12 HOUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dimetane-Ten is a combination of brompheniramine (antihistamine) and phenylephrine (decongestant). Brompheniramine competitively blocks histamine H1 receptors, reducing allergic symptoms; phenylephrine acts as an α1-adrenergic receptor agonist, causing vasoconstriction in nasal mucosa.
Pseudoephedrine is a sympathomimetic amine that acts as an agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of nasal mucosa and reducing nasal congestion.
One tablet (chlorpheniramine maleate 4 mg, phenylephrine HCl 10 mg, methscopolamine nitrate 2.5 mg) orally every 12 hours, not to exceed 2 tablets in 24 hours.
120 mg orally every 12 hours, extended-release tablets. Maximum 240 mg per day.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours; clinical context: allows twice-daily dosing; prolonged in renal impairment.
8-10 hours in adults with normal renal function; prolonged to 19-24 hours in renal impairment (CrCl <30 mL/min); shorter in children (3-4 hours)
Renal: ~50% as unchanged drug and metabolites; biliary/fecal: ~40% as metabolites; remainder as minor pathways.
Renal: 74-95% as unchanged drug; 1-4% as active metabolite (norpsuedoephedrine); biliary/fecal: minimal (<1%)
Category C
Category C
Decongestant/Antihistamine Combination
Decongestant